Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Q1 sales

This article was originally published in The Tan Sheet

Executive Summary

Abbott Park, Ill.-based firm's Ross Products division's Q1 sales rose 3.8% to $604 mil., despite absence of revenue from Clear eyes eye drops, Murine eye and ear care products, which were divested to Prestige Brands International last quarter (1"The Tan Sheet" Jan. 20, 2003, In Brief). Sales increase likely was due to Ross' introduction of infant formulas fortified with docosahexaenoic acid and arachidonic acid...

You may also be interested in...



Abbott OTCs divested

Ross Products parent records $30 mil. in Q4 from sale of Clear eyes eye drops, Murine eye drops and ear care products to Prestige Brands International. Deal was completed Dec. 30, according to Abbott, which says divested brands were profitable but no longer fit its strategic direction. Abbott expressed similar rationale for selling Selsun Blue dandruff shampoo line to Chattem last year (1"The Tan Sheet" March 11, 2002, p. 5). Sales for Ross division, which markets Similac infant formula and Ensure, Glucerna adult nutritionals, rose 3.4% in Q4 to $502 mil. but were flat for the year at $2.09 bil. During Jan. 16 analysts call, Abbott Medical Products Group President & COO Richard Gonzalez announces two "strategic introductions" for adult nutritionals segment in 2003 - Ensure in a plastic, reclosable container, and retail launch of Prosure, a product for weight loss in oncology patients that is currently available in the institutional segment...

EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.

Topics

UsernamePublicRestriction

Register

PS017586

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel